Simplify Logo

Full-Time

Associate Director Medical Information & Review

Posted on 7/19/2024

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

501-1,000 employees

Develops therapies for neurological disorders

Biotechnology
Healthcare

Compensation Overview

$146k - $182.4kAnnually

+ Bonus + Equity Awards

Senior, Expert

San Diego, CA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Communications
Marketing
Requirements
  • Requires a PharmD, PhD, or MD in a scientific discipline
  • Targeting 5+ years of prior MI and MLR experience in pharmaceutical or biotech industry or relevant experience in medical affairs, medical communications, scientific affairs or similar area. Previous experience in neurology or rare disease is preferred. An equivalent combination of relevant education and experience may be considered
  • Collaborates cross-functionally to align Medical Information deliverables with the needs of the stakeholders (MSLs, Commercial, HEOR, R&D, etc.)
  • Maintains expert understanding of product knowledge and labeling, associated disease states, relevant literature, treatment guidelines, competitor information, and brand strategies and tactics for the therapeutic areas involved
  • Ability to work effectively, coordinate, and lead a multi-disciplinary, cross-functional team
  • Experience in literature searches, literature evaluation, and drug information concepts
  • Strong analytical and problem-solving skills
  • Understanding of the legal and regulatory environment of pharmaceutical industry desired
Responsibilities
  • Works with MI vendor on handling inquiries received by the MICC and ensures accurate and timely responses to unsolicited medical information requests received
  • Manages MICC inquiry escalations and provide guidance to medical team members for specific requests that require escalation
  • Leads the development of verbal responses (FAQs) and standard response letters (SRLs)
  • Develops medical content for scientific exchange (e.g. slide decks, medical booth content)
  • Creates and maintains the FAQ and SRL database for products in market and in pipeline
  • Independently evaluates literature, interprets complex data, writes effectively, articulates information to a variety of audiences, and effectively negotiates with counterparts from cross-functional areas
  • Oversee the development of MI Reports to assist with the identification of data gaps
  • Coordinates with Medical Affairs colleagues, vendors and/or outsourced providers in the development, review and approval of medical materials; provides medical guidance and expertise to MLR and MRC teams in the review of promotional and medical materials during MLR/MRC meetings; participates in the review of promotional materials and medical materials to ensure medical accuracy
  • Maintains understanding of product knowledge and labeling, associated disease states, relevant literature, treatment guidelines, competitor information, and marketing strategies and tactics for assigned therapeutic area(s)
  • Serves as subject matter expert on both general and specific Medical Review practices and provides executable recommendations to senior stakeholders as needed
  • Develops MLR/MRC trainings to provide to cross functional subject matter experts on MRC policy and MLR responsibilities to ensure consistent review process and rapid response with the aim of delivering high quality material
  • Provide support for the surveillance of various compendia
  • Ensure compliance with applicable regulations, industry standards, and company policies related to medical information
  • Anticipates risk and implements strategies to avoid potential problems. When appropriate, elevates to supervisor and other appropriate functional leaders as needed
  • Other duties as assigned
Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. Their products are created through extensive research and development, followed by rigorous clinical trials to ensure safety and effectiveness. Once approved by regulatory bodies like the FDA, these therapies are marketed to patients and healthcare providers. Acadia stands out from competitors by concentrating on areas with significant unmet medical needs and fostering strategic partnerships to enhance their research and market presence. The company's goal is to improve the quality of life for individuals with neurological conditions through effective treatments.

Company Stage

IPO

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's launch of Magnolia's Guide to Adventuring showcases their innovative approach to raising disease awareness and redefining perceptions of Rett syndrome.
  • The acceptance of trofinetide for priority review by Health Canada could lead to significant market expansion and first-mover advantage in treating Rett syndrome in Canada.
  • The appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development, signals a strong commitment to advancing their R&D capabilities.

What critics are saying

  • The failure of the Phase III ADVANCE-2 trial for pimavanserin in schizophrenia highlights the high-risk nature of drug development in the biopharmaceutical sector.
  • Dependence on regulatory approvals, such as the FDA and Health Canada, introduces uncertainty and potential delays in bringing therapies to market.

What makes Acadia Pharmaceuticals Inc. unique

  • Acadia Pharmaceuticals focuses exclusively on neurological disorders, setting it apart from competitors with broader therapeutic areas.
  • Their commitment to corporate social responsibility, including initiatives like the Rett Sibling Scholarship, enhances their reputation and community engagement.
  • Acadia's strategic partnerships and corporate sponsorships amplify their research capabilities and market reach, distinguishing them from competitors who may not leverage such collaborations.
INACTIVE